Gladstone Institutes
1650 Owens Street
San Francisco
California
94158
United States
105 articles with Gladstone Institutes
-
New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease
10/8/2019
The biotech company MedaRed, Inc. is founded on groundbreaking basic research from Gladstone Institutes, UC San Francisco, and UC San Diego.
-
The 2019 Ogawa-Yamanaka Stem Cell Prize Awarded to Gordon Keller
7/31/2019
Keller’s work with pluripotent stem cells has led to a platform for disease modeling and regenerative medicine.
-
Dragon Heart
7/29/2019
First sequence of the Komodo dragon genome reveals clues about its evolution.
-
A New Cellular Framework to Study Causes of Birth Defects
7/24/2019
Gladstone scientists reveal how gene mutations can alter small groups of cells and result in congenital heart disease.
-
A New Director of Cardiovascular Research at Gladstone
7/1/2019
Benoit Bruneau is selected to lead the Gladstone Institute of Cardiovascular Disease.
-
Here are some of the top research stories that happened around the industry this week.
-
A Stepping Stone to Increase Diversity in Biomedical Research
5/9/2019
The National Institutes of Health renews its funding of a promising internship program at the Gladstone Institutes.
-
Chemical Modifiers Tag-Team to Regulate Essential Mechanism of Life
5/2/2019
Basic science discovery explains a fundamental way human cells differ from yeast cells.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
New Method to Detect Off-Target Effects of CRISPR
4/19/2019
Since the CRISPR genome editing technology was invented in 2012, it has shown great promise to treat a number of intractable diseases.
-
Cell Press Partners with the Gladstone Institutes to support the Ogawa-Yamanaka Stem Cell Prize
4/1/2019
This annual prize supports the brightest scientists using cellular reprogramming for regenerative medicine
-
Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.
-
A New Culprit of Cognitive Decline in Alzheimer’s Disease
2/5/2019
It has long been known that patients with Alzheimer’s disease have abnormalities in the vast network of blood vessels in the brain. Some of these alterations may also contribute to age-related cognitive decline in people without dementia. However, the ways in which such vascular pathologies contribute to cognitive dysfunction have largely remained a mystery. Until now, that is.
-
Proteins Use a Lock and Key System to Bind to DNA
1/16/2019
You can think of DNA as a string of letters—As, Cs, Ts, and Gs—that together spell out the information needed for the construction and function of cells.
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-
Two Possible New Ways to Treat Silent Seizures in Children
1/2/2019
An unexpected brain region is important for Dravet Syndrome, finds study.
-
Drug Targets for Ebola, Dengue, and Zika Viruses Found in Lab Study
12/13/2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes and UC San Francisco may finally change that.
-
Seth Shipman Joins the Gladstone Institutes
11/19/2018
Shipman will build new technologies to understand the development of the brain.
-
New Insights into the Aging Brain
11/12/2018
Gladstone scientists uncover new gatekeeper function of anti-aging molecule.
-
New Immunotherapy Targeting Blood-Clotting Protein Protects Multiple Sclerosis and Alzheimer’s Disease Models
10/15/2018
Gladstone researchers have stopped the detrimental effects of blood-brain barrier leaks.